Results 181 to 190 of about 8,837,414 (325)

An evolving scenario in the study of illuminated manuscripts: innovative approaches to research questions

Alessandra Chirivì, Eva Pietroni, Matteo Greco, Andrea Pandurino, Alberto Bucciero   +4 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Variability in sodium content of takeaway foods: Implications for public health and nutrition policy. [PDF]

PLoS One
Mavrochefalos AI, Dodson A, Kuhnle GGC.
europepmc   +1 more source

Supplemental document for Manuscript 575949

Andrea Mazzolini
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Uralenol, Glycyrol, and Abyssinone II as potent inhibitors of fibroblast growth factor receptor 2 from anti-cancer plants: A deep learning and molecular dynamics approach. [PDF]

PLoS One
Hossain A, Hossan MS, Prodhan MS, Joy MNH, Siam MR, Rahman ME, Matin MN.   +6 more
europepmc   +1 more source

They're veGAN but they almost taste the same: generating simili-manuscripts with artificial intelligence

, 2023
Jean-Baptiste Camps, Chahan Vidal-Gorène   +1 more
openalex   +2 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Tests of the Oddity Effect Hypothesis in mixed-species parid flocks. [PDF]

PLoS One
Selman ZA, Frazier EK, Adams CB, Freeberg TM.   +3 more
europepmc   +1 more source

Manuscript Drafts

, 2018
Sara LePine, Samantha F. Anderson, Dana C. Leighton, Jon Grahe, Nicole Legate   +4 more
openalex   +1 more source